Reyes-Méndez MÁ, Juárez-Figueroa L, Iracheta-Hernández P, Medina-Islas Y, Ruiz-González V

Language: English
References: 11
Page: 337-342
PDF size: 93.71 Kb.

ABSTRACT

Background. Patients exposed to hepatitis C virus (HCV) may develop chronic infection with viremia. The diagnosis of this condition requires the use of several laboratory tests in algorithms tailored to the population and resources available for each laboratory. Aim. We compared the diagnostic efficacy of two diagnostic algorithms for the identification of viremic patients with HCV. One based on confirmation of reactive antibody results with molecular techniques (reverse transcription polymerase chain reaction, RTPCR) and the other based on the use of a new HCV core antigen test (HCV Ag). Material and methods. We measured levels of anti-HCV, HCV Ag and viral load (trough RT-PCR) in parallel, in 211 samples (53 antibody positive, 158 antibody negative). Using the three results available for each sample we simulated the diagnostic performance of the two algorithms and compared them to the results of RT-PCR as gold standard. Results. Both algorithms showed a high degree of concordance for viremic patients. The percentage of correctly classified patients was 99.05% for the algorithm based on RT-PCR and 98.10% for the HCV Ag algorithm. The HCV core Ag test showed a clinical sensitivity of 0.917 and showed a good correlation to the results of molecular biology. Spearman rank correlation coefficient (ρ) of 0.97 (95% CI 0.95 to 0.99, p ‹ 0.0001). Conclusion. An algorithm incorporating HCV Ag as confirmatory test for anti-HCV results is a feasible alternative to the use of molecular techniques in laboratories that do not have access to them or require faster turn around times.

REFERENCES

1. World Health Organization. Hepatitis C: Fact Sheet No. 164. World Health Organization 2011. Available at: http:// www.who.int/mediacentre/factsheets/fs164/en/ index.html

2. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and Projections of Hepatitis C epidemiology in Latin America. Liver International 2011; 31: S18-S29.

3. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, et al. An assay for circulating antibodies to a major etiologic virus of non A non B hepatitis. Science 1989; 244: 362-4.

4. Cornish N. Laboratory diagnosis and evaluation of treatment for HCV. College of American Pathologists. CAP Today 2005; 78.

5. Albeldawi M, Ruiz-Rodriguez E, Carey WD. Hepatitis C virus, prevention, screening and interpretation of assays. Cleve Clin J Med 2010; 77: 616-26.

6. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazulli T. Heptitis C core antigen and its clinical applicability: Potential advantages and disadvantages for diagnosis and follow up. Rev Med Virol 2012; 22: 156-65.

7. Medici MC, Furlini G, Rodella A, Fuentes A, Monachetti A, Calderaro A, Galli S, et al. Hepatitis C virus core antigen: analytical performance, correlation with viremia and potential applications of a quantitative automated assay. J Clin Virol 2011; 51: 264-9.

8. Ghany MG, Strader DB, Thomas DL, Seef LB, American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.

9. Alter MJ, Kuhnert WL, Finelli L. Guidelines for Laboratory Testing and Result Reporting of Antibody to Hepatitis C Virus. Morbidity and Mortality Weekly Report 2003; 52; 1-16.

10. Contreras AM, Ochoa-Jiménez RJ, Celis A, Méndez C, Olivares L, Rebolledo CE, Hernandez-Lugo I, et al. High Antibody level: an accurate serologic marker of viremia in asymptomatic people with hepatitis C infection. Transfusion 2010; 50: 1335-43. Doi: 10.1111/j.1537-2995.2009. 02571.x.

11. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, et al. Performance and Clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46:210-5.